How Null Bites makes money.

A protein-design company that only publishes papers is a lab. Null Bites has to sell. Once a candidate clears simulation and the bench, the same molecule can become a license, a B2B ingredient, or a food product under our own brand. We will take the fastest serious route first.

Door 01 · Licensing the formulation.

Licensing is the first route. A formulation that clears simulation, fermentation, and bench testing can become IP that an existing food company pays to use. We run the design and validation. A partner with supply chain and distribution takes it to market. This is the lowest capex revenue in the model, which matters early.

Door 02 · Selling the ingredient.

The second route is selling the ingredient itself. Null Bites can produce the protein through fermentation or a partner route, then sell it as a B2B input to brands that know their category better than we do. That gives us manufacturing learning before we fight for consumer shelf space.

Door 03 · Making the food.

The third route is the finished food most people picture first. It is also the most expensive one to earn: brand, packaging, distribution, repeat purchase, returns. We should only do it when the designed protein is obviously better than the commodity substitute.

Every dollar of revenue should feed back into the engine that designs the next generation of food.

How the three doors compound.

Licensing and ingredient sales should fund the design loop before the brand carries the company. The loop then produces the few candidates good enough to deserve a consumer product. That keeps us from betting the whole company on one SKU.

The rough sequence: first license inside 12 to 18 months, first ingredient sales in year two, own-brand food after the molecule has proven itself. Across the next decade, the goal is simple: every rupee of revenue pays for more designs, better bench data, and better food. The result should be better proteins at lower cost, sold through the route that makes sense first.